BoomRay Novartis Radioligand License Deal
Analysis based on 7 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The deal is a modest positive for Novartis, adding a preclinical radioligand asset to its oncology pipeline at limited upfront cost, while validating the RLT space for investors. For privately held BoomRay, the up to USD 900 million in potential payments and royalties materially improves its funding outlook and credibility, though the undisclosed preclinical nature limits immediate market reaction.
Boomray Pharmaceuticals Co., Ltd. announced on September 22, 2026 that it has entered into an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset. Under the terms, BoomRay is eligible to receive up to USD 900 million, comprising an upfront payment plus development, regulatory, and sales milestone payments, with potential royalties on future global net sales. The deal pairs BoomRay's discovery and development capabilities in precision oncology radiopharmaceuticals with Novartis's global RLT expertise and commercial reach. BoomRay CEO Bo Shan called the agreement a significant milestone and validation of the company's discovery capabilities, while Shivam, Global Head of Oncology, Biomedical Research at Novartis, said the agreement complements Novartis's growing radioligand therapy portfolio and reflects its strategy of combining external innovation with internal R&D. BFC Partners acted as financial advisor to BoomRay. The asset remains preclinical and undisclosed, so near-term revenue impact is limited, but the transaction strengthens Novartis's oncology pipeline and provides BoomRay with substantial milestone-based funding and global development support.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard